ANI Pharmaceuticals, Inc.
ANIP
$75.42
-$1.12-1.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.64% | 53.58% | 53.12% | 43.43% | 44.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.64% | 53.58% | 53.12% | 43.43% | 44.75% |
| Cost of Revenue | 20.08% | 48.06% | 36.97% | 48.58% | 56.32% |
| Gross Profit | 37.10% | 57.67% | 63.65% | 40.57% | 36.86% |
| SG&A Expenses | 26.95% | 10.08% | 65.05% | 57.49% | 45.79% |
| Depreciation & Amortization | 0.06% | 43.71% | 58.41% | 55.87% | 48.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.92% | 29.30% | 55.70% | 48.82% | 52.57% |
| Operating Income | 885.92% | 334.81% | 26.47% | -0.35% | -65.50% |
| Income Before Tax | 328.74% | 207.31% | 560.21% | -21.11% | -1,553.22% |
| Income Tax Expenses | 214.43% | 197.97% | -- | -39.59% | -1,575.96% |
| Earnings from Continuing Operations | 367.52% | 210.14% | 473.81% | -13.87% | -989.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 367.52% | 210.14% | 473.81% | -13.87% | -989.70% |
| EBIT | 885.92% | 334.81% | 26.47% | -0.35% | -65.50% |
| EBITDA | 104.02% | 683.46% | 43.95% | 27.41% | 7.11% |
| EPS Basic | 323.43% | 193.59% | 902.61% | -16.50% | -1,592.66% |
| Normalized Basic EPS | 658.51% | 215.61% | 53.46% | -9.21% | -246.27% |
| EPS Diluted | 313.31% | 189.21% | 885.65% | -16.91% | -1,604.93% |
| Normalized Diluted EPS | 630.64% | 210.01% | 49.92% | -9.69% | -247.95% |
| Average Basic Shares Outstanding | 6.38% | 3.45% | 2.66% | 2.66% | 2.33% |
| Average Diluted Shares Outstanding | 11.98% | 8.70% | 5.11% | 3.21% | 1.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | 1.77% | 1.27% | 0.16% | -1.11% |